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Abstract
Goals of work Bone pain and functional impairment are
major concerns for multiple myeloma (MM) patients. The
goal of this study was to better define the role of
percutaneous cementoplasty (PC) in improving their quality
of life.
Materials and methods This retrospective analysis included
28 consecutive heavily pretreated MM patients managed at
our institution between 1996 and 2002. They underwent a
total of 34 PC procedures for the treatment of 117 vertebrae
and 2 iliac sites and were evaluated at 1 month.
Main results Significant pain reduction of >50% was
obtained after 83% of the procedures, with a mean visual
analogous score decreasing from 7.48/10 to 2.1/10
(p<0.001). It resulted in a complete interruption of opiate
analgesic consumption after 59.3% of the procedures, with
a mean decrease of 70.4% in the opiate dose. Functional
impairment was evaluated with the Eastern Cooperative
Oncology Group (ECOG) performance status scale, with
mean scores improving from 1.9 to 0.86 after the
procedures (p=0.001). There was no major complication.
Conclusion PC is a safe, feasible, and efficient approach for
the treatment of bone pain and disability in MM patients.
Keywords Bone metastasis . Pain . Vertebral compression
fracture . Vertebroplasty
Introduction
Although currently available therapies have significantly
prolonged disease-free and overall survival, multiple
myeloma (MM) remains an incurable disorder, character-
ized by frequent relapses and ultimate resistance to
antitumoral agents. Hence, skeletal morbidity contributes
persistently to alter the quality of life of many myeloma
patients, despite the recognized impact of localized or even
extended radiation therapy, biphosphonates [16], and
surgical interventions [9, 30].
Initially used for the treatment of benign conditions
such as hemangioma and osteoporotic fractures [4, 10,
12], percutaneous cementoplasty (PC) has since been
shown to provide significant pain relief in bone lesions
resulting from diverse metastatic neoplasia [11, 14, 17,
21]. Indications for PC and patient selection have been
extended [3, 5, 15, 18, 23, 28] to be applied to flat
vertebrae and also to extravertebral sites. Studies with
limited numbers of patients have also documented the
beneficial effects of PC for management of vertebral
compression fractures related to MM [2, 6, 24].
This study describes the effects of PC in a retrospective
series of 28 consecutive MM patients treated at our
institution between 1996 and 2002, who suffered from
refractory pain related to bone infiltration by the disease,
with or without associated bone fractures.
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Materials and methods
Patients
We reviewed nonselected MM patients subjected to PC
between 1996 and 2002 at our institution. MM diagnosis
was made on the basis of the presence of a monoclonal
protein, bone manifestations, and on bone marrow plasma
cell infiltration [8]. Staging was established according to
Durie–Salmon criteria [7]. Patients’ characteristics (n=28)
are summarized in Table 1. Most of the patients were
heavily pretreated, with bone pain refractory to conven-
tional therapies. Indications for PC were systematically
debated preoperatively by a multidisciplinary team, includ-
ing a neurosurgeon, an orthopedic surgeon, a medical
oncologist, a radio-oncologist, an anesthesiologist, and
interventional radiologists. Decision to perform PC was
made when spontaneous or palpation elicited pain correlat-
ed with radiological evidence of tumoral infiltration, using
computed tomography (CT) scan and/or magnetic reso-
nance imaging. Adjacent levels, which are known to be at
increased risk for secondary fractures [1], were sometimes
also treated by PC. According to current experience [27],
radicular pain, epidural extension, and spinal cord com-
pression were not considered as strict exclusion criteria;
however, in these cases (n=8), PC was combined with
steroids, surgery, or radiation therapy.
Percutaneous cementoplasty
PC procedures were performed under local anesthesia when
a single vertebral level was treated (n=7) and under short
general anesthesia when two or more levels were treated
(n=27). A postero-lateral transpedicular approach was used
for vertebral lesions, as previously described [20, 22]. One
patient underwent extraspinal cementoplasty in the pelvis
bone, using the approach reported by Kelekis et al. [19].
Before polymethylmethacrylate (PMMA, lopamidol, lopa-
miro 300; Bracco, Milan, Italy) injection, contrast venog-
raphy was always performed to map the venous outlets and
predict possible leakage pathways (Fig. 1). The needle was
repositioned in cases where the risk of venous embolization
was considered too high. PMMA opacified with barium
sulfate was then injected under fluoroscopic guidance
(biplanar fluoroscopic angiography suite, BV 3000; Philips
Medical Systems, Best, The Netherlands), with careful
observation for potential PMMA extra-osseous leaks. The
mean volume of PMMA injected in each vertebra was
3.1 ml (range 1.5–7.5 ml), and a total of 8-ml PMMA was
injected for the pelvic procedure. Finally, a post-cemento-
plasty CT scan was performed within 24 h to document any
PMMA leakage. Post-cementoplasty thoracic X-rays or CT
scan were performed in case of extra-osseous cement
leakages detected by bone CT scan (n=8) or symptoms
suggesting pulmonary embolization (n=2).
Clinical assessment and statistical analysis
The objective of this studywas to investigate the potential effect
of PC on pain and disability. Clinical outcome was assessed by
one of us (NNTT) by comparing pre- and post-cementoplasty
(day 30) pain scores, analgesic consumption, and performance
status (PS). Pain score was assessed using a visual analogue
scale (VAS) ranging from 0 (no pain) to 10 (maximal pain) [13].
Percentage of pain reduction was calculated using the
following formula: Percentage of pain reduction=100×
[(VAS before PC−VAS after PC)/VAS before PC]. PS was
determined with the ECOG scale [29]. Statistical analysis was
performed using a Student’s t-test to compare pain scores. As
the PS has only five levels, the assumption of a normal
distribution is not possible, and we used the Mann–Whitney
rank sum test, a nonparametric test, instead of the t-test, to
assess difference in PS before and after PC.
Results
Patients
A total of 117 vertebrae, including 75 fractures, were treated
by PC in 33 sessions (n=27 patients). In one additional
Table 1 Initial patient characteristics
Male/female 17/11 (61%/39%)
Median age 65 (40–89)
Median elapsed time from diagnosis to PC 66 months (0–132)
Stage I 3 (11%)
Stage II 4 (14%)
Stage III 21 (75%)
IgG 21 (75%)
IgA 5 (18%)
Light chains 2 (7%)
Previous treatments
CT 1 line 10 (36%)
CT≥2 lines 15 (54%)
ASCT×1 3 (11%)
ASCT≥2 9 (32%)
Thalidomide 12 (43%)
Levels treated
Dorsal vertebrae 57 (42a)
Lumbar vertebrae 59 (33a)
Sacrum 1
Others (pelvis) 1 (1a)
CT Chemotherapy, ASCT autologous stem cell transplantation
a Number of fractures among the levels treated.
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patient, iliac and acetabular PMMA injections were per-
formed for extensive pelvis involvement. Mean number of
vertebrae that were treated in one session was 3.27, with a
range from 1 to 9, and the different levels treated are shown
in Table 1. Median follow-up after PC was 41 months (range
3–81), during which there was no clinical evidence of
progressive disease at the sites of cement implantation. Five
patients suffering from pain occurring later on at other sites
received additional PCs. One of them had a total of three
procedures over 5 months (Fig. 2).
Most patients required further therapies for MM progres-
sion, which always arose out of the sites previously treated by
PC. At the time of data analysis, eight deaths had occurred, six
from chemotherapy-related complications. The patient who
underwent the pelvic procedure received a second autologous
stem cell transplantation, followed by thalidomide and
bortezomib treatments. She died from chemotherapy-related
adverse events 2 years after the PC, but without progressive
disease at the sites of cement implantation.
Safety and complications
The tolerance for the procedure was excellent for all patients.
As assessed by control CT scan performed shortly after the
intervention, eight cement leakages were documented (24%).
They were, however, of small size (<1 cm) and clinically not
relevant. A single cement leakage along the L5 nerve root was
correlated with the appearance of a transient sensitive defect in
this territory, which resolvedwithin 3 weeks. Two patients had
transient thoracic pain or dyspnea after PC, but pulmonary
embolization was excluded in both cases by lung CT scan and
pulmonary scintigraphy.
Efficacy
To determine efficacy of the procedure, three parameters were
analyzed at day 30: pain control through VAS scores, decrease
in opiate analgesics consumption, and ambulation/autonomy
through PS scale. According to current experience, day 30
represents a valuable time point to assess the stability of PC
efficiency [25]. At that time, outcome data were available for
30/34 procedures, four patients being lost for follow-up.
Pain control
Mean VAS fell down from 7.48 (range 4–10) before PC to
2.1 (range 0–10) after PC (p<0.001). This represents a 70–
100% pain reduction for 21 procedures (70%), a 50–69%
pain reduction for 4 PC procedures (13.3%), and a low
response (0–49% of pain relief) after 5 procedures (16.7%).
Opiate analgesic consumption
Consumption of opiate analgesics was reported for every
patient before and after PC, with three patients who did not
take any opiate or derivatives before the procedure. Opiate
consumption could be interrupted after 16/27 procedures
(59.3%) and partially reduced after 6/27 (22.2%). Only five
Fig. 1 Venography followed by
vertebroplasty of a L3 compres-
sion fracture. a and b Antero-
posterior and lateral views of the
venography, respectively, with a
small epidural leak (arrow). Ve-
nography here reflects classical
vascular distribution as usually
seen in MM. c and d Results of
the vertebroplasty procedure,
with adequate filling of the
vertebral body, without leakage
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patients had to maintain their preoperative level of opiates.
Overall, we noted a mean decrease in opiate dose of 70.4%.
Performance status
Most patients had major ambulation problems related to
pain secondary to fractures and bone infiltration, interfering
with their daily occupations and impairing their autonomy.
Mean PS improved from 1.9 to 0.86 after PC (p=0.001).
Variations of the number of patients for each PS score
before and after PC are shown in Fig. 3. No patient
experienced worsening of ambulatory capacities.
Discussion
This retrospective analysis of heavily pretreated (median
time from diagnosis to PC: 66 months) MM patients
showed that PC may induce a rapid and sustained decrease
in pain related to tumor bone infiltration and, consequently,
Fig. 2 Vertebroplasty at multiple levels (76-year-old patient). Lateral
(a) and axial (b) CT scan views: result of PC in one step at seven
levels (D9 to L1, L3, L5) in this patient with debilitating dorso-
lumbar pain secondary to multiple compression fractures. A small
PMMA leakage is observed on the axial view of L1 (arrow). c Two
months later, the patient presented with a painful fracture of L2,
which was located between two previously treated vertebrae.
Panoramic view of the total eight levels treated. d Two months later,
pain recurred secondary to a D7 compression fracture. D6 and D8,
which showed vertebral body and pedicular infiltration, were also
treated by PC. Lateral view after D6–D9 PC. Outcome was excellent,
with only minimal pain and full autonomy for more than 3 years
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Fig. 3 Performance status scores before and after PC. The proportion
of patients in each level of PS—according to the ECOG scale—is
shown before and after PC. 0 Fully active, able to carry on all pre-
disease performance without restriction. 1 Restricted in physically
strenuous activity but ambulatory and able to carry out work of a light
or sedentary nature. 2 Ambulatory and capable of all selfcare but
unable to carry out any work activities, up and about more than 50%
of waking hours. 3 Capable of only limited selfcare, confined to bed
or chair more than 50% of waking hours. 4 Completely disabled.
Cannot carry on any selfcare. Totally confined to bed or chair
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a major reduction in opiate analgesic consumption. The
benefit provided by PC is also revealed by the overall
improvement in ambulatory capacities and daily occupa-
tional abilities of the patients, as shown by the better ECOG
scale after the procedure. Despite inclusion of severely
compromised patients, no major adverse effect was ob-
served, with a single case of transient L5 sensitive defect
secondary to cement leakage. Overall, these observations
suggest that PC is an attractive new therapeutic approach
for improving the quality of life of MM patients.
Our data confirm and extend those recently reported in a
few studies exploring the PC or kyphoplasty in MM
(summarized in Table 2). In these studies, the number of
treated patients was limited, the procedure was usually
performed on a single or a small number of vertebrae, and
mainly, compression fractures were considered for PC or
kyphoplasty. In this paper, we show in a larger series of
patients that PC can be applied to several levels within the
same procedure, with a median of three vertebrae treated in
a single step (range 1–9). Our data also suggest a benefit
from PC even in the absence of MM-induced bone fracture.
For MM patients with a long history and diffuse bone
involvement, restricting PC to the more symptomatic
vertebrae or compression fracture could be deleterious in
view of the well-known risk of fracture in involved
vertebrae neighboring a cemented level [1, 24]. Extending
PC to non-broken vertebrae (37% in our series) might
considerably improve the antalgic effect obtained by the
procedure. Indeed, pain relief by PC at one defined level
might sometimes uncover pain in surrounding vertebrae,
and we actually observed that the pain killing effect was
less complete when a single vertebra was treated. There-
fore, in the particular case of MM, we propose to consider
PC not only for compression fractures but also for adjacent
vertebrae involved with the tumoral process.
With a median follow-up of 41 months after PC, we did
not see any evidence of progression at the site of PC, while
all patients relapsed eventually or even died from MM. This
clinical observation supports the hypothesis of an anti-
tumor effect mediated by hyperthermia arising during
PMMA polymerization, as suggested by extended tumor
necrosis observed in and around PMMA [26].
Due to the simultaneous advances in transplantation
strategies and in innovative therapies, MM patients expe-
rience longer survival, underlining the importance of
quality of life issues. Whether PC has to be considered as
a first-line option for symptom management—in conjunc-
tion with other standard therapies—or as a saving option
Table 2 Reports of percutaneous cementoplasty in multiple myeloma patients
Procedure Nb of
patients
Median
age
Nb of levels
treated
%
Levels
fractured
%
Cement
leakage
Outcome:
pain relief
Outcome:
functional
amelioration
Complications
Cotten
et al. [3]
Vertebroplasty 8 59.5 10 NA 60 Mild to
marked pain
relief in all
patients
NA None
Dudeney
et al. [6]
Kyphoplasty 18 63.5 55 100 4 Improvement
in pain
Improvement
in function
None
Diamond
et al. [5]
Vertebroplasty 7 68 14 100 0 75%
Improvement
in pain scores
50–60%
Improvement
in
functional
status
None
Bartolozzi
et al. [2]
Percutaneous
vertebroplasty
and
kyphoplasty
14 54 19 (10
vertebroplasties
and 9
kyphoplasties)
100 NA Improvement
in VAS (9/10
to 3/10)
amelioration
in
Karnofsky
(50 to 70)
None
Ramos
et al.
[24]
Percutaneous
vertebroplasty
12 66 19 100 84 Improvement
in VAS (7.5/
10 to 3.7/10)
Improvement
in ECOG
(3.1 to 2.5)
None
Present
study
Percutaneous
cementoplasty
28 65 119 63 24 Improvement
in VAS
(7.48/10 to
2.1/10)
Improvement
in ECOG
(1.9 to
0.86)
1 Transient
sensory loss
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for long-lasting bone pain refractory to established thera-
pies remains to be better defined. This should be the issue
of large-scale prospective studies in the future.
References
1. Barr JD, Barr MS, Lemley TJ, McCann RM (2000) Percutaneous
vertebroplasty for pain relief and spinal stabilization. Spine
25:923–928
2. Bartolozzi B, Nozzoli C, Pandolfo C, Antonioli E, Guizzardi G,
Morichi R, Bosi A (2006) Percutaneous vertebroplasty and
kyphoplasty in patients with multiple myeloma. Eur J Haematol
76:180–181
3. Cotten A, Dewatre F, Cortet B, Assaker R, Leblond D,
Duquesnoy B, Chastanet P, Clarisse J (1996) Percutaneous
vertebroplasty for osteolytic metastases and myeloma: effects of
the percentage of lesion filling and the leakage of methyl
methacrylate at clinical follow-up. Radiology 200:525–530
4. Cotten A, Boutry N, Cortet B, Assaker R, Demondion X, Leblond
D, Chastanet P, Duquesnoy B, Deramond H (1998) Percutaneous
vertebroplasty: state of the art. Radiographics 18:311–320
5. Diamond TH, Hartwell T, Clarke W, Manoharan A (2004)
Percutaneous vertebroplasty for acute vertebral body fracture
and deformity in multiple myeloma: a short report. Br J Haematol
124:485–487
6. Dudeney S, Lieberman IH, Reinhardt MK, Hussein M (2002)
Kyphoplasty in the treatment of osteolytic vertebral compression
fractures as a result ofmultiple myeloma. J ClinOncol 20:2382–2387
7. Durie BG, Bataille R (1989) Therapeutic implications of myeloma
staging. Eur J Haematol, Suppl 51:111–116
8. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro
M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G,
Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J,
Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman
D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P,
Tricot G, Van Ness B (2003) Myeloma management guidelines: a
consensus report from the Scientific Advisors of the International
Myeloma Foundation. Hematol J 4:379–398
9. Durr HR, Wegener B, Krodel A, Muller PE, Jansson V, Refior HJ
(2002) Multiple myeloma: surgery of the spine: retrospective
analysis of 27 patients. Spine 27:320–324
10. Evans AJ, Jensen ME, Kip KE, DeNardo AJ, Lawler GJ, Negin
GA, Remley KB, Boutin SM, Dunnagan SA (2003) Vertebral
compression fractures: pain reduction and improvement in
functional mobility after percutaneous polymethylmethacrylate
vertebroplasty retrospective report of 245 cases. Radiology
226:366–372
11. Fourney DR, Schomer DF, Nader R, Chlan-Fourney J, Suki D,
Ahrar K, Rhines LD, Gokaslan ZL (2003) Percutaneous verte-
broplasty and kyphoplasty for painful vertebral body fractures in
cancer patients. J Neurosurg 98:21–30
12. Galibert P, Deramond H, Rosat P, Le Gars D (1987) Preliminary
note on the treatment of vertebral angioma by percutaneous
acrylic vertebroplasty. Neurochirurgie 33:166–168
13. Grossman SA, Sheidler VR, Swedeen K, Mucenski J, Piantadosi
S (1991) Correlation of patient and caregiver ratings of cancer
pain. J Pain Sympt Manag 6:53–57
14. Halpin RJ, Bendok BR, Liu JC (2004) Minimally invasive
treatments for spinal metastases: vertebroplasty, kyphoplasty, and
radiofrequency ablation. J Support Oncol 2:339–351
15. Hentschel SJ, Rhines LD, Shah HN, Burton AW, Mendel E (2004)
Percutaneous vertebroplasty in vertebra plana secondary to
metastasis. J Spinal Disord Tech 17:554–557
16. Hoskin PJ (2003) Bisphosphonates and radiation therapy for
palliation of metastatic bone disease. Cancer Treat Rev 29:321–327
17. Kallmes DF, Jensen ME (2003) Percutaneous vertebroplasty.
Radiology 229:27–36
18. Kaufmann TJ, Jensen ME, Schweickert PA, Marx WF, Kallmes
DF (2001) Age of fracture and clinical outcomes of percutaneous
vertebroplasty. Am J Neuroradiol 22:1860–1863
19. Kelekis A, Lovblad KO, Mehdizade A, Somon T, Yilmaz H,
Wetzel SG, Seium Y, Dietrich PY, Rufenacht DA, Martin JB
(2005) Pelvic osteoplasty in osteolytic metastases: technical
approach under fluoroscopic guidance and early clinical results.
J Vasc Interv Radiol 16:81–88
20. Kim AK, Jensen ME, Dion JE, Schweickert PA, Kaufmann TJ,
Kallmes DF (2002) Unilateral transpedicular percutaneous
vertebroplasty: initial experience. Radiology 222:737–741
21. Martin JB, Jean B, Sugiu K, San Millan RD, Piotin M,
Murphy K, Rufenacht B, Muster M, Rufenacht DA (1999)
Vertebroplasty: clinical experience and follow-up results. Bone
25:11S–15S
22. Martin JB, Wetzel SG, Seium Y, Dietrich PY, Somon T, Gailloud
P, Payer M, Kelekis A, Ruefenacht DA (2003) Percutaneous
vertebroplasty in metastatic disease: transpedicular access and
treatment of lysed pedicles—initial experience. Radiology
229:593–597
23. Peh WC, Gilula LA (2003) Percutaneous vertebroplasty: indica-
tions, contraindications, and technique. Br J Radiol 76:69–75
24. Ramos L, Las Heras JA, Sanchez S, Gonzalez-Porras JR,
Gonzalez R, Mateos MV, San Miguel JF (2006) Medium-term
results of percutaneous vertebroplasty in multiple myeloma. Eur J
Haematol 77:7–13
25. Roila F, Lupattelli M, Sassi M, Basurto C, Bracarda S,
Picciafuoco M, Boschetti E, Milella G, Ballatori E, Tonato M
(1991) Intra and interobserver variability in cancer patients’
performance status assessed according to Karnofsky and ECOG
scales. Ann Oncol 2:437–439
26. San Millan RD, Burkhardt K, Jean B, Muster M, Martin JB,
Bouvier J, Fasel JH, Rufenacht DA, Kurt AM (1999) Pathology
findings with acrylic implants. Bone 25:85S–90S
27. Shimony JS, Gilula LA, Zeller AJ, Brown DB (2004) Percutane-
ous vertebroplasty for malignant compression fractures with
epidural involvement. Radiology 232:846–853
28. Stallmeyer MJ, Zoarski GH, Obuchowski AM (2003) Optimizing
patient selection in percutaneous vertebroplasty. J Vasc Interv
Radiol 14:683–696
29. Taylor AE, Olver IN, Sivanthan T, Chi M, Purnell C (1999)
Observer error in grading performance status in cancer patients.
Support Care Cancer 7:332–335
30. Walker MP, Yaszemski MJ, Kim CW, Talac R, Currier BL (2003)
Metastatic disease of the spine: evaluation and treatment. Clin
Orthop Relat Res S165–S175
896 Support Care Cancer (2008) 16:891–896
